1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AC710F4A4F2E69DA00258A1A0034D044
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-oncology-msl-team-excellence-benchmarking-roles-staffing-levels?opendocument
18
19opendocument
2018.206.194.21
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Field Medical Excellence

Oncology MSL Team Excellence: Benchmarking Roles and Staffing Levels

ID: 5774


Features:

10 Info Graphics

8 Data Graphics

80+ Metrics

7 Narratives


Pages/Slides: 23


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Oncology MSL Team Excellence: Benchmarking Roles and Staffing Levels”

STUDY OVERVIEW

In the ever-evolving landscape of cancer treatments, Oncology field medical teams play a pivotal role in establishing strong relationships with Key Opinion Leaders (KOLs) and Healthcare Professionals (HCPs).

To effectively navigate this changing engagement model, Oncology field medical leaders must ensure their roles and expectations are well-aligned to best support stakeholders and deliver unparalleled value.

Best Practices, LLC undertook benchmarking research to identify current and emerging trends in the management of Oncology field medical teams, particularly in the context of virtual and hybrid Medical Science Liaisons (MSLs). This study provides Oncology field medical leaders with the insights needed to optimize roles and staffing levels to ensure effective engagement.


KEY TOPICS

  • Oncology Staffing Levels: Traditional MSLs vs. Hybrid MSLs
  • Drivers of Oncology Field Team Evolution
  • Medical vs. Commercial Field Resourcing

KEY METRICS

  • How many MSLs and senior MSLs of each type (Traditional MSLs vs. Hybrid MSLs vs. Virtual MSLs) are currently staffed to the Oncology field team?
  • Average number of Oncology MSLs; MSL-to-senior MSL ratio at benchmark Oncology organizations
  • How effective are each of the listed MSL job roles in Oncology segment?
  • How critical have each of the listed factors been in shaping the current size and composition of roles within the Oncology field team?
  • Predicted changes in Oncology MSL staffing levels over the next 12-24 months
  • How many staff (FTEs) are currently allocated to the listed Oncology field team roles?
  • Sales rep-to-MSL ratio at benchmark Oncology organizations

SAMPLE KEY FINDINGS

  • Assessing MSL effectiveness by type: Field-based and hybrid MSLs are rated as similarly effective by benchmark organizations. In terms of future investment, 53% of field leaders predict slight-to-moderate growth in hybrid MSL staffing levels over the next 2 years, while 42% predict slight-to-moderate growth in field-based staffing levels.

METHODOLOGY

Best Practices, LLC engaged Field Medical and other Medical Affairs leaders from 20 top Oncology manufacturers in this research through a benchmark survey. Deep-dive interviews were also conducted with field medical leaders to capture additional insights.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Health Care; Chemical


Companies Profiled:
AstraZeneca; Astellas; Bayer; Clovis Oncology; Eisai; Eli Lilly and Company; EMD Serono; GE Healthcare; Genentech; Ipsen; Kyowa Kirin; MacroGenics; Merck; Merus; Novartis; Pfizer; Rain Oncology; Roche; Servier; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.